Brief: Turnstone Biologics To Present Preclinical Data For Selected Tumor-Infiltrating Lymphocyte Therapy
28/09/2023 11:04
Sept 28 (Reuters) - Turnstone Biologics Corp TSBX.O :
* TURNSTONE BIOLOGICS TO PRESENT PRECLINICAL DATA FOR
SELECTED
TUMOR-INFILTRATING LYMPHOCYTE (TIL) THERAPY AT SOCIETY FOR
IMMUNOTHERAPY OF CANCER’S (SITC) 38TH ANNUAL MEETING
Source text for Eikon: ID:nGNX6ph8nB
Further company coverage: TSBX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Turnstone Biologics
See all newsBrief: Turnstone Biologics to Be Acquired by XOMA for $0.34/Share Plus Contingent Value Right
U.S. STOCKS ON THE MOVE-Walmart, crypto, banks
Turnstone rises as company cuts job, changes executives
Brief: Turnstone Biologics Sees One-Time Severance-Related Charge Associated With Workforce Reduction To Be About $2.3 Million
Brief: Turnstone Biologics Announces Strategic Restructuring To Prioritize Portfolio And Extend Financial Runway